Alembic Pharma (ALPM) delivered better-than-expected 4QFY24 earnings,led by better gross margin and improved off-take in the API segment. Aftertwo consecutive years of weak financial performance, ALPM ended FY24with 10%/14%/43% YoY growth in sales/EBIDTA/PAT to INR62b/INR9.3b/INR6b.